Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2024-210830

Published: 2024

Journal Articles

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Blood (2024) 144 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2024-209164

Published: 2024

Journal Articles

Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Abida Babu, Kathryn Bower, Madiha Siraj, Biwei Cao, Jongphil Kim, Hany Elmariah, Rawan Faramand, Sayeef Mirza, Lia Perez, Asmita Mishra, Farhad Khimani, Jose L. Ochoa-Bayona, Michael Nieder, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan

Blood (2024) 144 (Supplement 1): 4881.

https://doi.org/10.1182/blood-2024-202709

Published: 2024

Journal Articles

Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Blood (2024) 144 (Supplement 1): 4871.

https://doi.org/10.1182/blood-2024-208229

Published: 2024

Journal Articles

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Blood (2023) 142 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2023-192022

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Teresa Caprice, Wenyi Fan, Jongphil Kim, Rawan Faramand, Asmita Mishra, Lia Perez, Farhad Khimani, Aleksandr Lazaryan, Jose L. Ochoa-Bayona, Hien Liu, Michael D. Jain, Michael Nieder, Claudio Anasetti, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan, Hany Elmariah

Blood (2023) 142 (Supplement 1): 390.

https://doi.org/10.1182/blood-2023-186738

Published: 2023

Journal Articles

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Hany Elmariah, Jongphil Kim, Asmita Mishra, Rawan Faramand, Lia Perez, Aleksandr Lazaryan, Farhad Khimani, Hien Liu, Jose L. Ochoa-Bayona, Michael Nieder, Nicholas Figura, Timothy J Robinson, Taiga Nishihori, Claudio Anasetti, Joseph A. Pidala, Nelli Bejanyan

Blood (2023) 142 (Supplement 1): 4900.

https://doi.org/10.1182/blood-2023-187473

Published: 2023

Journal Articles

Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS

Hassaan Yasin, Mahrukh Naqvi, Jongphil Kim, Rawan Faramand, Omar Alexis Castaneda Puglianini, Farhad Khimani, Aleksandr Lazaryan, Taiga Nishihori, Michael Nieder, Joseph Pidala, Nelli Bejanyan

Blood (2022) 140 (Supplement 1): 4886–4888.

https://doi.org/10.1182/blood-2022-170696

Published: 2022

Journal Articles

Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Blood (2022) 140 (Supplement 1): 7638–7640.

https://doi.org/10.1182/blood-2022-168400

Published: 2022

Journal Articles

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Blood (2022) 140 (Supplement 1): 10488–10490.

https://doi.org/10.1182/blood-2022-170337

Published: 2022

Journal Articles

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia

Omar Albanyan, Syeda Mahrukh Hussnain Naqvi, Qianxing Mo, Athena Belfon, Eric Gaskill, Taiga Nishihori, Rawan Faramand, Aleksandr Lazaryan, Doris K. Hansen, Farhad Khimani, Asmita Mishra, Michael Nieder, Lia Perez, Hien D. Liu, Joseph Pidala, Claudio Anasetti, Frederick L. Locke, Nelli Bejanyan, Hany Elmariah

Blood (2022) 140 (Supplement 1): 7664–7666.

https://doi.org/10.1182/blood-2022-166008

Published: 2022

Journal Articles

Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients

Giacomo Adoncecchi, MS, Ambuj Kumar, MD MPH, Rawan Faramand, MD, Hien D. Liu, MD, Farhad Khimani, MD, Asmita Mishra, MD, Michael Nieder, MD, Taiga Nishihori, MD, Lia Perez, MD, Joseph Pidala, MD, Claudio Anasetti, MD, Nelli Bejanyan, MD, Hany Elmariah, MDMS

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-141966

Published: 2020

Journal Articles

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Joseph Pidala, MD, Kelly Walton, Hany Elmariah, MDMS, Jongphil Kim, PhD, Asmita Mishra, MD, Nelli Bejanyan, MD, Taiga Nishihori, MD, Farhad Khimani, MBBS, Lia Perez, MD, Rawan Faramand, MD, Marco L. Davila, MD PhD, Michael Nieder, MD, Nicholas Lawrence, PhD, Harshani Lawrence, PhD, Claudio Anasetti, MD, Said Sebti, PhD, Brian C. Betts, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-133874

Published: 2020

Journal Articles

Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience

Hamza Hashmi, MD, Jeffrey Lancet, MD, Asmita Mishra, MD, Kendra L. Sweet, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Lia Perez, MD, Farhad Khimani, MD, Michael Nieder, MD, Hany Elmariah, MD MS, Joseph Pidala, MD, Nelli Bejanyan, MD, Alan F. List, MD, Claudio Anasetti, MD, Taiga Nishihori, MD

Blood (2019) 134 (Supplement_1): 5739.

https://doi.org/10.1182/blood-2019-128985

Published: 2019

Journal Articles

CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Hany Elmariah, MD MS, Syeda Mahrukh Hussnain Naqvi, MD MHS, Jongphil Kim, PhD, Taiga Nishihori, MD, Asmita Mishra, MD, Lia Perez, MD, Hien D. Liu, MD, Farhad Khimani, MD, Michael Nieder, MD, Joseph Pidala, MD, Nelli Bejanyan, MD

Blood (2019) 134 (Supplement_1): 3329.

https://doi.org/10.1182/blood-2019-129437

Published: 2019

Journal Articles

Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant

Sayeef Mirza, MDMPH, Ankita Tandon, DO, Dakota Jenneman, MD, Shu Cao, MD, Ambuj Kumar, MD MPH, Michelle R. Kidd, PharmD, Farhad Khimani, MD, Asmita Mishra, MD, Hien D. Liu, MD, Taiga Nishihori, MD, Lia Perez, MD, Nelli Bejanyan, MD, Joseph Pidala, MD, Michael Nieder, MD, Hany Elmariah, MD MS

Blood (2019) 134 (Supplement_1): 5673.

https://doi.org/10.1182/blood-2019-127370

Published: 2019

Journal Articles

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Blood (2019) 134 (Supplement_1): 4621.

https://doi.org/10.1182/blood-2019-130922

Published: 2019

Journal Articles

Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Review and Meta-Analysis

Mudit Dutta, BS, Rahul Mhaskar, MPH, Hany Elmariah, MD MS, Taiga Nishihori, MD, Bijal Shah, MD, Michael Nieder, MD, Lia Perez, MD, Rawan Faramand, MD, Joseph Pidala, MD, Nelli Bejanyan, MD, Farhad Khimani, MD

Blood (2019) 134 (Supplement_1): 4773.

https://doi.org/10.1182/blood-2019-131126

Published: 2019

Journal Articles

Expression Level Of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry Might Correlate With Adverse Clinic Outcome In Adult B- Lymphoblastic Leukemia (B-ALL)

Jiangchuan Tao, MD, PhD, Bijal D. Shah, MD, Xiaohui Zhang, MD, Prerna Rastogi, MBBS, PhD, Jianguo Tao, MD, PhD, Jeffrey E Lancet, MD, Michael Nieder, Hui-Yi Lin, Ph.D, Eduardo M. Sotomayor, MD, Lynn Moscinski, MD, Ling Zhang, MD

Blood (2013) 122 (21): 3875.

https://doi.org/10.1182/blood.V122.21.3875.3875

Published: 2013

Journal Articles

Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial)

Blood (2013) 122 (21): 543.

https://doi.org/10.1182/blood.V122.21.543.543

Published: 2013

NARROW

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS

Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia

Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience

CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Review and Meta-Analysis

Expression Level Of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry Might Correlate With Adverse Clinic Outcome In Adult B- Lymphoblastic Leukemia (B-ALL)

Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only